Migraine HeadacheNeuroCareNCT07015411
Neuro-Complex & Multi Supplements for Migraine Prevention
A study testing Neuro-Complex and Multi in people with Migraine Headache and Migraine, run by Benfida, a department of Handi-Move at 1 site in Belgium.
Trial summary
The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Migraine Headache, Migraine, Migraine in Adults
- What is being tested?
- Neuro-Complex and Multi
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteBelgium
- Study dates
- 15 May 2025to 16 Dec 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female between 18 and 75 years;
- Diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura)
- At least 5 attacks fulfilling the criteria below
- Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
- Headache has at least two of the following characteristics
- unilateral location
Show all 18Show fewer
- pulsating quality
- moderate or severe pain intensity
- aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)
- During headache at least one of the following:
- nausea and/or vomiting
- photophobia and phonophobia
- Not attributed to another disorder
- Migraine frequency of at least 6 headache days per month during the last 3 months;
- Stable body mass index (BMI) between 18.5-35.0;
- Stable medication use with no significant changes in prophylactic or acute migraine treatments in the past 3 months, and willingness to maintain or reduce (if not needed) this throughout the study period;
- Willingness and ability to complete an ediary (mobile app or web based) and to follow the instruction of the study;
- Having signed an informed consent.
Who cannot join
- Other primary head pain disorders such as but not restricted to tension-type headache, cluster headache, fibromyalgia;
- Secondary head pain due to trauma, injury, infections;
- Medication overuse for headache defined as acute headache medication >10-15 days per month depending on the half-life of the medication (left to PI discretion);
- Severe medical conditions affecting absorption and metabolism of the product, including but not restricted to chronic use of laxatives;
- Bariatric surgery;
- Severe psychiatric conditions that could interfere with diary compliance or assessment of the product (e.g., severe depression or cognitive impairments) left to investigator discretion;
Show all 20Show fewer
- Use of other dietary supplements that could potentially affect migraines, unless willing to discontinue them before the study begins (wash out period of 3 months);
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
- Women of childbearing potential without medically effective form of contraception unless they can confirm they've had bilateral tubal ligation or that their male partner has had a vasectomy;
- Specific allergies or intolerance to components of the product;
- Recent migraine interventions: Such as Botox injections (except if considered as a stable treatment, i.e. not the first injection), nerve blocks, or other invasive treatments in the last 6 months;
- Concurrent participation in another clinical study or having participated in the last 3 months:
- Swallowing disorders;
- Chronic drug and alcohol abuse;
- Anticoagulants (coumarin compound);
- Hepatic or biliar truct disorders;
- Active malignancy and immunosuppression therapy;
- Hypothyroidism;
- Close collaborators of investigational team, of sponsor or of study coordinator;
- Under guardianship or judiciable protection.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
Meclinas
Mechelen, 2800
Ine Vercammen, 0032 15 79 27 97, ine.vercammen@meclinas.com
Elisa Debien, 0032 15 79 27 97, elisa.debien@meclinas.com
About this study
Official title: Effectiveness of an Orally Administered and Combined Neuro-Complex & Multi Supplements in the Prevention of Migraine in Adult
The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura).
The main endpoint of this clinical trial is :
Read more
The mean changes in migraine days per month (MDM) after 8 weeks of supplementation.
Participants will:
Orally consume two caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).
- Conditions
- Migraine Headache, Migraine, Migraine in Adults
- Being tested
- Neuro-Complex and Multi
- Keywords
- Migraine, Neuro-Complex, Multi, Supplement, headache, nutrients
- Medical subject headings
- Migraine Disorders, Headache
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuro-Complex and MultiDietary supplement
Participants will orally consume 2 caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).
Participants will take 1 cap of each product simultaneously twice a day directly in their mouth.
| Study group | Role | What they receive |
|---|---|---|
| Supplementation Arm - Neuro-Complex and Multi Combination | Experimental | Not described Receives: Dietary Supplement: Neuro-Complex and Multi |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction of migraine days per month (MDM) by 25% by using the combined supplementation with Neuro-Complex & Multi after 8 weeks of product intake
Mean change of migraine days per month (MDM)
Measured: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Secondary outcomes (23)
Evaluate the effect on migraine intensity/severity after 8 weeks of product intake
Mean change in migraine intensity/severity measured using a numerical rating scale after 8 weeks of product intake
Measured: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on migraine duration after 8 weeks of product intake
Mean change in migraine duration defined as start date and end date of each migraine episode captured by the patient
Measured: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on symptoms associated with migraine after 8 weeks of product intake
Mean change in symptoms measured using a 5-likert scale
Measured: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on quality of life (QoL) after 8 weeks of product intake
Mean change in QoL assessed using self-reported questionnaire (SF-36)
Measured: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on number of responders to the supplementation after 8 weeks of product intake
Proportion of responders defined as patients with ≥50% reduction in MDM
Measured: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
• Evaluate the effect on reduction in the use of acute medication for migraine after 8 weeks of product intake
Mean change in days of use of acute medication against migraine
Measured: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on patient tolerance after 8 weeks of product intake
Mean change in number of Adverse events (AE)
Measured: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on migraine days per month (MDM) after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Mean change of migraine days per month (MDM)
Measured: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on migraine intensity/severity after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Mean change in migraine intensity measured using a numerical rating scale
Measured: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on migraine duration after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Mean change in migraine duration defined as start date and end date of each migraine episode captured by the patient
Measured: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on symptoms associated with migraine after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Mean change in symptoms measured using a 5-likert scale
Measured: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on quality of life (QoL) after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Mean change in QoL assessed using self-reported questionnaire (SF-36)
Measured: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on number of responders to the supplementation after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Proportion of responders defined as patients with ≥50% reduction in MDM
Measured: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on reduction in the use of acute medication for migraine after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Mean change in days of use of acute medication against migraine
Measured: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on patient tolerance after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Mean change in number of Adverse events (AE)
Measured: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Compare the effect on migraine days per month (MDM) between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Mean change of migraine days per month (MDM)
Measured: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on migraine intensity/severity between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Mean change in migraine intensity measured using a numerical rating scale
Measured: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on migraine duration between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Mean change in migraine duration defined as start date and end date of each migraine episode captured by the patient
Measured: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on symptoms associated with migraine between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Mean change in symptoms measured using a 5-likert scale
Measured: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on quality of life (QoL) between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Mean change in QoL assessed using self reported questionnaire (SF-36)
Measured: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on number of responders to the supplementation between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Proportion of responders defined as patients with ≥50% reduction in MDM
Measured: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on reduction in the use of acute medication for migraine between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Mean change in days of use of acute medication against migraine
Measured: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on patient tolerance between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Mean change in number of Adverse events (AE)
Measured: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2025
- Study start15 May 2025
- Primary completion15 Dec 2025 (estimated)
- Study completion16 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Migraine HeadacheStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Benfida, a department of Handi-Move
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Artialis
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07015411
- Sponsor's protocol ID
- 001
- Acronym
- NeuroCare
- Status last verified
- Jun 2025
- First submitted
- 19 May 2025
- Last updated
- 11 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of an Orally Administered and Combined Neuro-Complex & Multi Supplements in the Prevention of Migraine in Adult
- ClinicalTrials.gov ID
- NCT07015411
- Acronym / sponsor ID
- NeuroCare / 001
- Conditions
- Migraine Headache, Migraine, Migraine in Adults
- Keywords
- Migraine, Neuro-Complex, Multi, Supplement, headache, nutrients
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Benfida, a department of Handi-MoveIndustry (pharma, biotech, devices)
- Collaborators
- Artialis
- Study start
- 15 May 2025 (actual)
- Primary completion
- 15 Dec 2025 (estimated)
- Study completion
- 16 Dec 2025 (estimated)
- First posted
- 11 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura).
The main endpoint of this clinical trial is :
The mean changes in migraine days per month (MDM) after 8 weeks of supplementation.
Participants will:
Orally consume two caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Supplementation Arm - Neuro-Complex and Multi Combination | Experimental | Dietary Supplement: Neuro-Complex and Multi |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Male or female between 18 and 75 years;
- Diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura)
- Migraine frequency of at least 6 headache days per month during the last 3 months;
- Stable body mass index (BMI) between 18.5-35.0;
- Stable medication use with no significant changes in prophylactic or acute migraine treatments in the past 3 months, and willingness to maintain or reduce (if not needed) this throughout the study period;
Key exclusion criteria (20 listed)
- Other primary head pain disorders such as but not restricted to tension-type headache, cluster headache, fibromyalgia;
- Secondary head pain due to trauma, injury, infections;
- Medication overuse for headache defined as acute headache medication >10-15 days per month depending on the half-life of the medication (left to PI discretion);
- Severe medical conditions affecting absorption and metabolism of the product, including but not restricted to chronic use of laxatives;
- Bariatric surgery;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuro-Complex and MultiParticipants will orally consume 2 caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2). Participants will take 1 cap of each product simultaneously twice a day directly in their mouth. | Dietary supplement | Supplementation Arm - Neuro-Complex and Multi Combination |
Primary outcome
Reduction of migraine days per month (MDM) by 25% by using the combined supplementation with Neuro-Complex & Multi after 8 weeks of product intake
Time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Mean change of migraine days per month (MDM)
23 secondary outcomes
Evaluate the effect on migraine intensity/severity after 8 weeks of product intake
Time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on migraine duration after 8 weeks of product intake
Time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on symptoms associated with migraine after 8 weeks of product intake
Time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on quality of life (QoL) after 8 weeks of product intake
Time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on number of responders to the supplementation after 8 weeks of product intake
Time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
• Evaluate the effect on reduction in the use of acute medication for migraine after 8 weeks of product intake
Time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on patient tolerance after 8 weeks of product intake
Time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)
Evaluate the effect on migraine days per month (MDM) after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Time frame: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on migraine intensity/severity after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Time frame: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on migraine duration after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Time frame: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on symptoms associated with migraine after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Time frame: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on quality of life (QoL) after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Time frame: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on number of responders to the supplementation after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Time frame: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on reduction in the use of acute medication for migraine after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Time frame: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Evaluate the effect on patient tolerance after 16 weeks (8 weeks without supplementation followed by 8 weeks of supplementation)
Time frame: Between Baseline (V0) and Week 16 (after 8 weeks of non-supplementation followed by 8 weeks of supplementation)
Compare the effect on migraine days per month (MDM) between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Time frame: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on migraine intensity/severity between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Time frame: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on migraine duration between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Time frame: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on symptoms associated with migraine between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Time frame: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on quality of life (QoL) between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Time frame: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on number of responders to the supplementation between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Time frame: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on reduction in the use of acute medication for migraine between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Time frame: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Compare the effect on patient tolerance between the non-supplementation period (baseline to 8 weeks) and the supplementation period (8 to 16 weeks)
Time frame: Between the non-supplementation period (Baseline to Week 8) and the supplementation period (Week 8 to Week 16)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2025.
Related trials for Migraine Headache
Active, not recruitingObservational study
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
Migraine
Active, not recruitingObservational study
Consistency of Response With Rimegepant in Acute Treatment of Migraine
Migraine
RecruitingObservational study
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Migraine
RecruitingPhase 3
Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)
Post Traumatic Headache
Active, not recruiting
Cocoa Extract for Migraine Trial
Migraine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neuro-Complex and Multi in people with Migraine Headache and Migraine, run by Benfida, a department of Handi-Move at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ine Vercammen (0032 15 79 27 97, ine.vercammen@meclinas.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction of migraine days per month (MDM) by 25% by using the combined supplementation with Neuro-Complex & Multi after 8 weeks of product intake (time frame: Between Week 8 (V1) and Week 16 (after 8 weeks of supplementation)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2025.